The PROLONG Trial - Rituximab Maintenance Therapy in ITP
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a two phase study that aims to evaluate if low-dose Rituximab maintenance
therapy may prolong the the effect of Rituximab in immune thrombocytopenia.
Phase:
Phase 3
Details
Lead Sponsor:
Ostfold Hospital Trust
Collaborators:
Cairo University Hospital, Egypt Centre Hôpital Universitaire Farhat Hached Centre Hôpital Universitaire Farhat Hached, Tunisia Hammersmith hospital, UK Hammersmith Hospitals NHS Trust Haukeland University Hospital Helse Stavanger HF Henri Mondor University Hospital Hopital La Rabta Odense University Hospital Oslo University Hospital St. Olavs Hospital Tunisian Military Hospital University Hospital of North Norway University Hospital, Akershus